Abdulla A. Damluji, MD, PhD Profile picture
Nov 15, 2021 12 tweets 11 min read Read on X
Great session #AHA2021

Cardiovascular Quality and Outcomes: An International Collaboration

@UmeshKhotMD @emilycob
The push for cardiovascular interventions on the interventional level - beyond the U.S.

Mark Huffman of @NorthwesternU
Funding on the international level.

$50 million from @nih_nhlbi and $30 million from @AHAScience to improve the global cardiovascular care.

#AHA2021
Implementation research and health policy on the global stage #AHAQCOR
Quality of Care Measurement Globally.

@rohan_khera @Yale
Electronic Healthcare Systems in the World and Utilization of Data: A Focus on Quality Assurance of Data.

Excellent!!

@hmkyale @rohan_khera
On Sex Disparities on Cardiovascular Health: A Global Perspective

@hvanspall
Representation of Women in Clinical Trials Beyond
Care of Women is Suboptimal Relative to Men.

The age standardized deaths among women by social and economic status
The social and economic status and prevalence of HF by gender

Lower income regions, women, and CVD mortality

@UmeshKhotMD
Heart Failure Trials Globally

Africa and Asia are underrepresented!
The road to the future is highlighted below:

#QCOR21

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Abdulla A. Damluji, MD, PhD

Abdulla A. Damluji, MD, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @DrDamluji

Jan 7
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: @NEJM

🥸 Vutrisiran is promising: congratulations to authors!

👇👇👇 Image
🥸 1/ ATTR-CM is a progressive, fatal disease. It occurs due to misfolded transthyretin proteins depositing in the heart muscle, causing infiltrative cardiomyopathy. Vutrisiran, an RNA interference agent, offers new therapy by targeting the production of hepatic transthyretin.
🥸 2/ The HELIOS-B trial evaluated vutrisiran in 655 patients with ATTR-CM. Patients were randomized 1:1 to receive vutrisiran (25 mg subcutaneously every 12 weeks) or placebo for up to 36 months.
Read 21 tweets
Dec 21, 2024
Atrial Fibrillation: @JAMA_current

🥸 Nice review in JAMA on AF by @darae_ko and team; congratulations.

😱 20-points here

👇👇👇 Image
🥸 1️⃣ Atrial fibrillation (AF) affects ~10.55 million US adults. It increases the risk of stroke, heart failure (HF), myocardial infarction, chronic kidney disease, dementia, and death.

😱Managing AF effectively is critical to improving CV outcomes.
🥸 2️⃣ AF symptoms range from palpitations, shortness of breath, chest pain, presyncope, and fatigue to being completely asymptomatic.

😱About 10-40% of people with AF don’t notice symptoms, which makes screening and incidental detection critical.
Read 23 tweets
Nov 17, 2024
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM

🥸The SUMMIT trial - @AHAScience

😱 Summary

👇👇👇 Image
🥸 1️⃣ Obesity drives heart failure with preserved ejection fraction (HFpEF) through systemic inflammation and visceral adiposity. Tirzepatide, a dual GIP and GLP-1 receptor agonist, offers weight loss and potential cardiovascular benefits.
🥸 2️⃣ The SUMMIT trial evaluated 731 HFpEF patients with obesity (BMI ≥30), randomized to tirzepatide or placebo for 52 weeks. Primary outcomes were a composite of cardiovascular death or worsening HF events and improvement in health status (KCCQ-CSS).
Read 21 tweets
Nov 17, 2024
Left Atrial Appendage Closure after Ablation for Atrial Fibrillation: @NEJM

🥸The OPTION trial: @AHAScience

😱 Summary

👇👇👇👇 Image
🥸 1️⃣ Oral anticoagulation is standard after atrial fibrillation (AF) ablation for stroke prevention but comes with bleeding risks and patient burdens. Left atrial appendage closure (LAAC) offers an alternative, but data comparing these strategies post-ablation have been limited.
🥸 2️⃣ The OPTION trial evaluated 1,600 patients post-AF ablation, randomized to LAAC (device group) or oral anticoagulation (anticoagulation group). Patients had a CHA2DS2-VASc score ≥2 (men) or ≥3 (women), indicating moderate-to-high stroke risk.
Read 21 tweets
Nov 17, 2024
Routine Spironolactone in Acute Myocardial Infarction: @NEJM

🥸 Great trials from #AHA24: @AHASc

😱 Summary

👇👇👇 Image
🥸 1️⃣ Aldosterone levels predict worse outcomes after myocardial infarction (MI).

😱High levels are associated with increased mortality, and therapies targeting aldosterone have shown promise in other cardiovascular conditions.
🥸 2️⃣ Spironolactone has reduced mortality in patients with chronic heart failure with reduced ejection fraction (HFrEF).

😱It’s a cornerstone therapy for managing HFrEF and reducing hospitalizations.
Read 22 tweets
Nov 1, 2024
Transcatheter Valve Replacement in Severe Tricuspid Regurgitation: @NEJM

🥸 TRISCEND II Trial - #TCT2024

😱 Summary

👇👇👇 Image
🥸 1️⃣ Severe tricuspid regurgitation leads to high symptom burden and increases risk of mortality.
🥸 2️⃣ This trial compared 400 patients with tricuspid regurgitation: valve replacement + medical therapy vs. medical therapy alone.
Read 17 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(